Nolato AB (NOLA-B) Fair Value & Analysis
Healthcare · SE · Market cap 13.1B SEK (≈ $1.4B) · ISIN SE0015962477
What is Nolato AB really worth?
A solid business, currently priced close to our fair value of kr 54.63.
Strengths
Risks
For context
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 22 days ago
Share price +7.4% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- The price sits in the lower half of our model range, the side with the larger margin of safety.
- The data supports the verdict: every model runs on fully documented inputs.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range kr 37.27 – kr 103.23 · fair‑value band kr 40.97 – kr 68.29 · the kr 53.00 price screens below the kr 54.63 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Nolato AB (NOLA-B) currently trades at kr 53.00, while our model-based Fair Value estimate is kr 54.63, implying the stock looks roughly 3.0% fairly valued today. The Quality Score stands at 63/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of kr 59.49 per share, and 16 of the 26 models we run sit above the kr 53.00 price. Bear case: the Asset-Based group reads lowest at kr 15.33, and 10 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Nolato AB generated revenue of 9.4B SEK at a net margin of 8.1%. Revenue declined 3.9% year over year. It earns a return on equity of 13.3%. Net debt stands at 972M SEK. Fundamentals as of Aug 13, 2026
Our scenario range runs from kr 40.97 (bear case) to kr 68.29 (bull case); at kr 53.00, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 15% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at 3%, NOLA-B screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly kr 0.7542 per share, which is 1.4 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: DCF Models (kr 59.49) versus Asset-Based (kr 15.33). Highest evidence: FCF DCF (80).
Notify me when NOLA-B reaches fair value
Put NOLA-B on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 51
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Nolato AB (publ) develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally. It operates through the Medical Solutions and Engineered Solutions segments.
Full company description
Nolato AB (publ) develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally. It operates through the Medical Solutions and Engineered Solutions segments. The company offers catheter balloons; breathing bags; non-conductive sealing and damping silicone products; primary plastic packaging for medicines; and crimp and dropper bottles. It also provides thermal heating pads, gap fillers, and paste under the Compatherm brand; Autolys M products, deep well plates, microtubes, PCR/qPCR products, pipettes and slim-line pipette tips, vial HP, and quality grades under the TreffLab by Nolato; and electromagnetic compatibility (EMC) products, including Compashield molded and extruded electromagnetic interference (EMI) shielding gaskets, Trishield, and MIL SPEC EMI shielding products. In addition, the company offers laboratory products, such as boxes with integrated lids; containers with hinged lids; sampling and transport tubes; spoons and cups; disposable tubes and containers; test tubes and ergonomic caps; and containers, vials, and slide tubes with push on lids. Further, it provides injection molding of plastic and silicone, injection blow molding, scientific and ceramic injection molding, dip and compression molding, and micro molding; extrusion and silicone sponge extrusion technologies; thermal management; decoration and cutting technologies; cleanroom production; assembly solutions; design and virtual prototyping solutions; and tool manufacturing. It serves medical technology, pharmaceutical, consumer electronics, telecom, automotive, hygiene, and other industrial sectors. The company was formerly known as Nordiska Latexfabriken i Torekov AB and changed its name to Nolato AB (publ) in 1982. Nolato AB (publ) was founded in 1938 and is headquartered in Torekov, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Nolato AB reported revenue of 9.5B SEK in FY2025 versus 11.6B SEK in FY2021, a compound −5.0%/yr. Reported net income was 777M SEK in FY2025, compounding −9.5%/yr from FY2021.
of which total revenue +8.8 % · buybacks/dilution −0.3 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch NOLA-B: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | −34% |
| Edwards Lifesciences Corporation EW | $89.78 | $41.02 | −54% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | −2% |
Compare Nolato AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Nolato AB (NOLA-B) overvalued or undervalued?
What is the fair value of NOLA-B?
What is the quality score of NOLA-B?
What is the revenue of Nolato AB (NOLA-B)?
What is the net profit margin of NOLA-B?
Does Nolato AB pay a dividend?
Watch Nolato AB in the live analysis
One click puts Nolato AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.